Company Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy.
It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.
DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
| Country | France |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 161 |
| CEO | Daniel Tassé |
Contact Details
Address: BAtiment IRO, 107 Av. de la REpublique Châtillon, 92320 France | |
| Phone | 33 1 55 42 78 78 |
| Website | dbv-technologies.com |
Stock Details
| Ticker Symbol | DBVT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001613780 |
| CUSIP Number | 23306J101 |
| ISIN Number | US23306J3095 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel Tassé | Chief Executive Officer and Director |
| Virginie Simone Jeanine Verrechia Boucinha M.B.A. | Chief Financial Officer |
| Dr. Pharis Mohideen M.D. | Chief Medical Officer |
| Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. | Chief Operations Officer |
| Jonathan Neely | Vice President and Head of Investor Relations |
| Michele F. Robertson | Chief Legal Officer |
| James Briggs | Chief Human Resources Officer |
| Kevin Trapp | Chief Commercial Officer |
| Alan Kerr | Senior Vice President and Head of Global Regulatory Affairs |
| Pascal Wotling | Chief External Manufacturing and Supply Chain Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 5, 2026 | 8-K | Current Report |
| Jun 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 3, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | SCHEDULE 13G/A | Filing |
| May 11, 2026 | ARS | Filing |
| May 11, 2026 | DEF 14A | Other definitive proxy statements |
| May 5, 2026 | 8-K | Current Report |